Thermo Fisher Expands Bioprocessing Capabilities with $4 Billion Acquisition of Solventum’s Purification and Filtration Division

In a strategic move to enhance its bioprocessing capabilities, Thermo Fisher Scientific has announced the acquisition of the Purification and Filtration business segment from Solventum, a spinoff of 3M. The deal, valued at $4 billion, positions Thermo Fisher to significantly expand its offerings in the biopharmaceutical manufacturing sector.

The acquired business is renowned for its high-quality filters and membranes that are critical in various global applications within the biopharmaceutical industry. This acquisition not only broadens Thermo Fisher’s portfolio but also strengthens its position as a leader in serving science and technology markets.

Dare: February 25, 2025.

Newsflash | Powered by GeneOnline AI

Author

Mark Chiang

Related Post

Regional

After 25 Years of Investment, Singapore’s Biomedical Ambition Shows Real Progress — but the Breakthrough Moment Still Has Not Arrived

2026-04-02

go prime

Clarity, Courage, and Global Scale: How WuXi Global Forum 2026 Is Shaping What Comes Next

2026-01-19

Prime

JPM 2026 Recap: Capital Markets Reopen, AI Moves to the Last Mile, Metabolic Stakes Climb

2026-01-15